Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022

Rhea-AI Summary

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) will announce its first quarter 2022 financial results before the U.S. market opens on May 11, 2022. A conference call and webcast will follow at 8:30 a.m. ET for investors to discuss the results. Xeris specializes in unique therapies for endocrinology, neurology, and gastroenterology, with three available products: Gvoke®, Keveyis®, and Recorlev®. The company aims to expand its pipeline with novel treatments utilizing its proprietary formulation technologies.

Positive

• Xeris has three commercially available products: Gvoke®, Keveyis®, and Recorlev®.
• The company is developing a robust pipeline of new therapies.

Negative

• None.

Conference call and webcast at 8:30am ET

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that the Company will release its first quarter 2022 financial results before the open of the U.S. financial markets on Wednesday, May 11, 2022. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results.

To pre-register for the conference call please use this link: https://www.incommglobalevents.com/registration/q4inc/10525/xeris-biopharma-first-quarter-2022-financial-results-conference-call-and-webcast/. After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Wednesday, May 25, 2022, at US: 1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 723527. In addition, a live audio of the conference call will be available as a webcast. To join the webcast, please visit “Events” on investor relations page of the Company’s website at www.xerispharma.com.

About Xeris Biopharma Holdings, Inc.

Xeris (Nasdaq: XERS) is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005246/en/

Investor Contact

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com

312-736-1237

Source: Xeris Biopharma Holdings, Inc.

FAQ

When will Xeris Biopharma release its first quarter 2022 financial results?

Xeris Biopharma will release its first quarter 2022 financial results on May 11, 2022.

What time is the Xeris Biopharma conference call?

The conference call will take place at 8:30 a.m. ET on May 11, 2022.

What are the current products offered by Xeris Biopharma?

Xeris currently offers Gvoke®, Keveyis®, and Recorlev®.

How can I access the Xeris Biopharma conference call?

You can access the conference call via registration at Xeris's investor relations web page.